• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
JNJ

JNJ

Johnson & Johnson

NYSEHealthcareDrug Manufacturers - GeneralUS

USD223.24

+0.35 (+0.16%)

Rating:B+

Company Profile

CEO

Joaquin Duato

IPO Date

1943-01-02

Sector

Healthcare

Industry

Drug Manufacturers - General

Exchange

NYSE

Country

US

Market Metrics

Open

$222.45

Prev. Close

$222.89

Day Low

$222.00

Day High

$224.93

52W Low

$149.04

52W High

$251.71

Market Cap

$537.39B

Volume

4.57M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

47.6%

Avg Negative

4.0%

Avg Neutral

48.3%

News Feed

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

prnewswire.com·5/28/2026·↑ positive

Is Johnson & Johnson (JNJ) a Buy as Wall Street Analysts Look Optimistic?

zacks.com·5/28/2026·↓ negative

J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?

zacks.com·5/28/2026·↑ positive

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

wsj.com·5/28/2026·↑ positive

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

businesswire.com·5/27/2026·↑ positive

Johnson & Johnson (JNJ) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

seekingalpha.com·5/27/2026·↑ positive

President Trump's Drug Pricing Policies Could Hurt Drugmakers' Profits. Time to Sell Pharma Stocks?

fool.com·5/26/2026·↑ positive

Why Johnson & Johnson Might Be the Smartest Dividend King to Buy in Today's Market

fool.com·5/25/2026·↑ positive

Two Paths to Growth: Johnson & Johnson vs AbbVie

247wallst.com·5/25/2026·↑ positive

Johnson & Johnson (JNJ) Outperforms Broader Market: What You Need to Know

zacks.com·5/21/2026·↑ positive